H. Ward Wolff

Ward Wolff was most recently executive vice president and chief financial officer of Sangamo Therapeutics, Inc., serving there from December 2007 until his retirement in March 2017. Mr. Wolff was formerly with Nuvelo, Inc., where he served as senior vice president, finance and chief financial officer until its restructuring in August 2007. Prior to joining Nuvelo, he was chief financial officer and senior vice president, finance, of Abgenix, Inc. until April 2006 when Abgenix merged with Amgen Inc. Prior to joining Abgenix, Mr. Wolff held financial management positions in both public and private emerging growth companies, including serving as senior vice president and chief financial officer of DoubleTwist, Inc., a life sciences company integrating genomic information and bioinformatics analysis tools. He began his career with Price Waterhouse, where he held a number of positions as a certified public accountant, including senior audit manager. In addition to Portola, he currently serves on the board of directors of Calithera Biosciences, Inc. and Sunesis Pharmaceuticals, Inc. Mr. Wolff received a B.A. in economics from the University of California, Berkeley, and an M.B.A. from Harvard Business School.